NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) today announced that it is offering to sell 9,600,000 shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. Barclays Capital Inc. is acting as sole book-running manager in this offering and ZIOPHARM has granted the underwriter a 30 day option to purchase up to 1,440,000 additional shares. The public offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
